These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 16127718)

  • 1. Ambulatory motor assessment in Parkinson's disease.
    Keijsers NL; Horstink MW; Gielen SC
    Mov Disord; 2006 Jan; 21(1):34-44. PubMed ID: 16127718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks.
    Keijsers NL; Horstink MW; Gielen SC
    Mov Disord; 2003 Jan; 18(1):70-80. PubMed ID: 12518302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tremor in Parkinson's disease: 24-hr monitoring with calibrated accelerometry.
    Thielgen T; Foerster F; Fuchs G; Hornig A; Fahrenberg J
    Electromyogr Clin Neurophysiol; 2004; 44(3):137-46. PubMed ID: 15125053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of tremor and bradykinesia in Parkinson's disease using a novel ambulatory monitoring system.
    Salarian A; Russmann H; Wider C; Burkhard PR; Vingerhoets FJ; Aminian K
    IEEE Trans Biomed Eng; 2007 Feb; 54(2):313-22. PubMed ID: 17278588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Movement parameters that distinguish between voluntary movements and levodopa-induced dyskinesia in Parkinson's disease.
    Keijsers NL; Horstink MW; Gielen SC
    Hum Mov Sci; 2003 Feb; 22(1):67-89. PubMed ID: 12623181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
    Gurevich TY; Shabtai H; Korczyn AD; Simon ES; Giladi N
    Mov Disord; 2006 Oct; 21(10):1663-6. PubMed ID: 16941467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa induced motor complications in Thai Parkinson's disease patients.
    Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
    J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypokinesia in Parkinson's disease: influence of age, disease severity, and disease duration.
    van Hilten JJ; Braat EA; van der Velde EA; Middelkoop HA; van Dijk JG; Lighart GJ; Roos RA
    Mov Disord; 1995 Jul; 10(4):424-32. PubMed ID: 7565821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
    Mizuno Y; Abe T; Hasegawa K; Kuno S; Kondo T; Yamamoto M; Nakashima M; Kanazawa I;
    Mov Disord; 2007 Oct; 22(13):1860-5. PubMed ID: 17618525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.
    van Hilten JJ; van der Zwan AD; Zwinderman AH; Roos RA
    Mov Disord; 1994 Jan; 9(1):84-8. PubMed ID: 8139609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment.
    Goetz CG; Stebbins GT; Shale HM; Lang AE; Chernik DA; Chmura TA; Ahlskog JE; Dorflinger EE
    Mov Disord; 1994 Jul; 9(4):390-4. PubMed ID: 7969204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal study of the motor response to levodopa in Parkinson's disease.
    Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
    Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.
    Yamada K; Goto S; Hamasaki T; Kuratsu JI
    Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination.
    Richards M; Marder K; Cote L; Mayeux R
    Mov Disord; 1994 Jan; 9(1):89-91. PubMed ID: 8139610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early treatment of Parkinson's disease with levodopa].
    Odekerken VJ; Post B; Verschuur CV; de Bie RM
    Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired awareness of movement disorders in Parkinson's disease.
    Amanzio M; Monteverdi S; Giordano A; Soliveri P; Filippi P; Geminiani G
    Brain Cogn; 2010 Apr; 72(3):337-46. PubMed ID: 19914762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment challenges in early stage Parkinson's disease.
    Tetrud J
    Neurol Clin; 2004 Oct; 22(3 Suppl):S19-33. PubMed ID: 15501364
    [No Abstract]   [Full Text] [Related]  

  • 20. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.